Focused on sales, customer success, and scaling partnerships.

- Lead / led the club's overall efforts for digital health, healthcare and life sciences and organized/co-organized 25 AI and life sciences events, including 5 major conferences. Raised over $150,000 for the club, targeted towards the MIT scholarship fund. - Includes organizing a well-attended and highly-rated conference event series: 'Artificial Intelligence in Healthcare' at JP Morgan for multiple years that gathered over 400-600 diverse attendees in each instance.- Currently, lead the digital health track, where I held monthly events for the year 2023-2024 and continue into 2024-2025 with a strong lineup and new volunteers - Consistently recruited and mentored other MIT alumni volunteers to success for the digital health track, with 9 active volunteers for the track per season- Conduct digital marketing campaigns to target attendees and sponsors.- Perform 'soup to nuts' work from speaker selection to fundraising, partner management, promotion and detailed event planning.===================Awards and other details:- (2024) Again nominated for MIT's “MacVicar Award”, a national award of MIT recognizing 'innovation, dedication, and impact' by MIT volunteers.- Received the 2019 'honor roll of service' from the MIT alumni association.- Exceeded fundraising target by 3X and was awarded the 'VIP volunteer of the year award' in 2018- (2019) Nominated for MIT's “MacVicar Award”, a national award of MIT recognizing 'innovation, dedication, and impact' by MIT volunteers.- Fundraised for the 2nd annual MIT AI conference 2018, which had a 2X increase in attendees vs. previous year (1300 attendees in 2018) and a 50.3% majority female speaker ratio: a first for the club and a rare occurrence in tech.

Founded and led Virtuo AI, where I recruited a technical cofounder and rapidly developed a working prototype of a virtual patient designed to train telehealth providers. This experience highlighted an important insight: while innovative, telehealth provider training addresses a ‘vitamin’ need rather than a ‘painkiller’ problem. With this understanding, I made the difficult decision to wind down Virtuo AI and pivot to explore more impactful opportunities. During this transition, as I engaged in customer research and refined a new hypothesis, I was recruited by Enara Health to lead their growth initiatives.

TeraRecon is the leading Advanced Visualization and AI Platform for Medical Imaging. TeraRecon delivers real time imaging decision support for radiology, cardiology, vascular surgery, and beyond. Experience 3D, AI, and full clinical workflow features working together to support the widest range of use-cases from a single solution. Led all product launch initiatives for the new EurekaAI platform, IntuitionNX advanced visualization platform in the cloud, TR Neuro product for neurovascular emergencies and neurology, cardiovascular, oncology and pulmonology suites. Responsible for: product roadmap, partnerships, cloud migration, marketing requirements, end market needs, external technical discussions and end to end product launches, including sales training, pricing and packaging. Preparation and presentation of board and investor presentations.- Drove +XX% year on year bookings growth via new offerings, price increases and RFQ participation.- Directing the platform strategy for EurekaAI. Managing the sourcing and structuring of complex deal structures with XX third party companies to expand clinical applications.- Leading IntuitionNX launch, cloud migration, FDA approval strategy & customer adoption for this $XXm platform.

Oura combines advanced sensor technology and a minimal design with an easy-to-use mobile app to deliver precise, personalized health insights straight from the most reliable source: your body.Advised on international growth plans and distributor offerings.

(Digital therapeutic) Applied VR received FDA Breakthrough Device designation to use its platform, including virtual headsets, as a digital therapeutic to treat treatment-resistant fibromyalgia and chronic intractable lower back pain.Guided go-to-market planning, product-sales interlock, financials, and resourcing (sales force planning and operations support needed). This included advising on which indications to pursue, channels to prioritize and launch timing.

- Executed an $XX million licensing agreement with a major pharmaceutical partner that involved phased deliverables and payments: Upfront, regulatory milestones, sales thresholds and royalties.- Sourced, initiated and conducted licensing, co-development and partnership deal discussions with bioprocessing companies, pharmaceuticals, health insurers, med tech companies (vascular, respiratory care and diabetes spaces), medical imaging vendors, population health players, and specialty applications (e.g. custom biosensors for organ transplantation).- Supported CEO in providing investor leads as well as financial data and business cases for fund-raising. Prepared and presented materials to investors and Board of Directors.

- Launched Lumee® Oxygen biosensor wireless platform for critical limb ischemia. Obtained CE approval on-time and on-quality.- Led all product management (upstream) and product marketing (downstream) efforts for Lumee Oxygen and Lumee Glucose.o Owned product roadmap; provided input on clinical roadmap. Worked closely with clinical, software and regulatory teams to prioritize where to spend our resources with maximal impact.o Designed and implemented all product market research: Represented and continually gathered voice of the customer to refine product definition.o Defined pricing and product configurations. Owned business modeling and forecasting. Built order-to-cash processes, reporting and fulfillment procedures. Created user instructions for new products. Conducted productivity exercise to reduce COGS by 80%.o Represented Profusa at major vascular conferences VIVA 2019, LINC 2020 and hit all major deliverables on-time and on-quality: customer feedback surveys, events, lead generation, attendance targets and cost. Exceeded targeted number of commercial leads at LINC 2020 by 50%.o Collaborated with clinical team to develop special programs at major industry meetings.- P&L ownership for the Lumee Oxygen product line

Cordis is an $800m global cardiovascular medical device manufacturer for diagnostic and interventional procedures.- Transformed the North America ($300M business) marketing function and redefined the go-to-market strategy. Grew core $100M MYNX product line by 10%.- Took TRYTON, the first FDA-approved bifurcated cardiac stent, to the market in the US.- Launched the ‘Savings for Growth’ program, targeting C-suite clinical and economic decision makers.- Drove the prioritization of assets and partnerships to expand Cordis’s product portfolio.- Re-trained the entire sales team (180 people) on key product messages for our top three product lines.

- Led all global marketing for Telehealth and Remote Patient Monitoring (digital health) business lines, through a critical period of transformation from being a Telehealth product vendor to a complete population health analytics provider.- Conducted all the marketing due diligence that guided Philips’ acquisition of Wellcentive (see: https://www.wellcentive.com/).Our in-home clinical programs give care teams the ability to collect patient health status remotely. This helps patients stay engaged, informed and connected to help when they need it while empowering care teams to achieve improved health outcomes for their populations.

- Co-founded a start-up business unit. Headed the development and commercialization of in-home clinical and consumer health programs that deliver care and enable teams to collect patient health status remotely. - Led product roadmap, ideation, conceptualization, workflow generation (consumer, therapist, physician), app feature definition and prioritization, UX and UI design, MVP plan, external clinical partnerships and product team leadership.- Raised $4M for 2 consecutive years to launch four digital health programs that lowered cost significantly and reduced admissions by up to 45%: Healthcare @ home in India for respiratory care, stroke therapy via gamification in China, a cardiovascular disease post-discharge platform in China (in collaboration with Peking University First Hospital), and MOM (Maternal Obstetric Monitor) in Indonesia.- Devised 'full stack' software, hardware and medical personnel delivery model: India Healthcare @ Home enrolled 2,000 respiratory patients in the first 6 months in 1 city and continues to expand to new use cases and cities.

Pivoted the direction of this start-up business unit that I was initially hired into (primary care and secondary care solutions) from a primary care focus to chronic care (see role above). Nevertheless, launched one high-impact primary care product that transformed the delivery model for primary care in rural populations: Maternal Obstetric Monitor (MOM).• The MOM program reduced anemia in pregnant women in Indonesia by 99% and showed a 3X increase in detection of very high-risk pregnancies. Later expanded to other countries in Southeast Asia.• Recognized with 'The Frost & Sullivan Best Practices Award' in 2015 for demonstrating outstanding achievement and superior performance in 'strategic product development.' See: https://ww2.frost.com/news/press-releases/frost-sullivan-lauds-philips-boosting-healthcare-delivery-emerging-markets-through-its-disruptive-technologies/

- Team leadership of 25 people. P&L (topline and margin) responsibility of a $50M business. In charge of both direct and partner channel sales.- Consistently exceeded operating plan with 45% growth over 2 years (2.5X the Installed base growth) and 53% contribution margin (130% vs. operating plan) by building a high performing team of 80% new (external to GE) hires and bringing structure, discipline and rigor to commercial operations.- Increased renewals and out-of-warranty capture rates by over 20 percent by staffing key coverage and commercial operations positions that drove rigor.- Won the 2014 GE Healthcare President’s club for highest service revenue growth globally (this is a very selective award, granted only to the top 5 commercial leaders in a 1900 people organization).- Presented with the CEO Innovation Award in 2013 for reshaping the services product offering portfolio and repositioning services from ‘cost center’ to 'value differentiator.'

- P&L leadership: managed 20 distributors and led the partner channel across Africa.- Achieved 2.5X growth in operating margin by executing focused policies and cost-avoidance strategies: enforced new parts returns process, implemented proactive solutions to warranty issues that led to 50% reduction in warranty costs.- Drove operational excellence: improved cash collection (25% reduction in days outstanding) and closed 2011 with zero overdue field modification upgrades.- Granted services’ General Management award for highest top line and margin growth.

- Responsible for commercial strategy and execution for a $200M emerging markets services business (Africa, Middle East, Russia, Turkey & Central Asia); both direct and partner channels.- Launched new service offerings to support double-digit growth in service contract revenue for 3 consecutive years.- Achieved $200M in orders through market segmentation initiatives and a newly launched value proposition at point of sale.- Attained 3X service contract pricing performance vs. prior year by right-fitting and enforcing discipline on price increases at renewal.- Awarded EMEA (Europe, Middle East, Africa) Sales and Marketing award for ‘driving growth via marketing.’

- $200M global business. Owned product launch, roadmap, feature definition, VOC, business plans, GTM strategy, competitive benchmarking, pricing, U.S./global sales training and exhibition support for GE’s Innova products. Managed end of life for GE’s Angio-CT Interventional Oncology product.- Drove +5 pt. increase in GE’s U.S. market share by launching five new software and hardware products that took to market advanced applications for vascular, spine, neurology and oncology.- Created product user requirements for next generation hybrid operating room and provided a comprehensive definition of the features and functions to the engineering team.- Built strong relationships with interventional key opinion leaders- Continuously aligned with clinical teams to integrate outputs into marketing proof points.

Harvard Medical School; Beth Israel Deaconess Medical Center. - Neuroradiology research fellow. Teamed up with neuro-interventionalist to study intracranial aneurysms.

Projects on M&A, organizational strategy, change management, pricing and inside sales. Sample:Corporate Strategy • Conducted due diligence on energy companies in an M&A strategy study for a US energy merchant and prioritized assets for purchase.• Prepared fact pack and proposal on a major retail bank’s strategy and organization.Operations• Implemented change management program in a telecom company aimed at completely restructuring the organization.• Developed financial performance metrics (KPIs) to evaluate the performance of a Japanese semi-conductor equipment manufacturer.Sales and Marketing • Doubled the sales of a client’s ADSL (high speed internet) offering through a set of targeted initiatives: prepared value proposition for telesales operation, trained sales force & helped set up sales booths.• Ran call center sales promotion for telecom client: created target customer lists, wrote sales script and trained/supervised call center operators on a day-to-day basis. Worked with product management team to monitor sales progress and reported final results to the CEO.• Advised on the go-to-market strategy of a second mobile entrant in a liberalizing Middle Eastern telecom market.• Prepared an “all you need to know” package on the pricing of chemicals.Completed McKinsey & Company's mini-MBA program.

(Feb. 2004 – Aug. 2004)Consultant for a start-up. Product Design and development:• Optimized the design of the VSTENT™ myocardial implant which provides a direct connection between left ventricle and coronary vessel